TEHR vs Telegra: Scope, Pricing and Migration

Which Telegra capabilities belong in a fair comparison?

Telegra’s official site describes intake, commerce, prescribing workflows, pharmacy routing, a branded portal and mobile app, an operations dashboard and APIs. The company’s domain is telegramd.com; it is distinct from the Telegram messaging service. These documented components make it a relevant integrated-platform comparison for TEHR.

TEHR’s proposed role is technology and administration under the brand’s identity, connected to independent clinical services and pharmacy coordination. The buyer should compare how the entire operation works, not whether both homepages use the phrase white label. Review the TEHR platform against the Telegra package actually offered to your business.

A branded mobile app, a web portal and an API can serve different priorities. Ask which experience your patients will use most, who maintains it and which capabilities depend on a plan upgrade. The operating team should see how a subscription change, clinical message and fulfillment exception appear across all relevant surfaces.

How do the documented capabilities compare?

All competitor statements below are dated as of October 22, 2026 and reflect the cited public pages. “Not stated on reviewed pages” means an unanswered question, not an absent capability. TEHR’s column describes its service model; program-specific scope belongs in the proposal.

How should you evaluate clinical and fulfillment responsibilities?

Telegra’s conditions page lists weight loss, longevity, TRT, HRT, sexual health, dermatology, hair loss, STI care and lab testing. Its standards page describes LabCorp and Quest integration and pharmacy vetting. Those are vendor scope statements, not a promise that every treatment is appropriate or available for every patient.

For TEHR, independent licensed providers make clinical decisions and the proposed program must be checked against state and eligibility requirements. Brands bring the audience and manage commercial identity; they do not purchase the right to direct medical care. Show that boundary in intake, consent, patient communications and support escalation.

Peptides need particularly clear language. Telegra’s conditions page labels them Coming Soon. TEHR’s selected peptide programs are pending and not open for prescribing or fulfillment. Neither should be presented as an available program solely because it appears in a product roadmap. A future regulatory change still requires program-specific review before any launch.

What does a fair cost comparison include?

Telegra’s pricing page lists Plus onboarding at $5,000 or three $1,750 installments, and Pro at $10,000 or three $3,500 installments. Those installment totals are $5,250 and $10,500. They are onboarding payments, not published ongoing monthly platform subscription prices.

The table also lists annual patient ID-verification charges and plan differences in pharmacy connections. It does not establish all recurring platform, clinical and fulfillment costs in the reviewed content. Request the complete fee schedule, including what happens after onboarding, rather than treating the setup amount as the total cost of running the service.

TEHR states a flat platform subscription plus flat transaction fee and 0% revenue share, with actual amounts provided in a scoped quote. Use TEHR pricing to define the proposed fee events, then compare identical patient journeys. A transaction fee, a clinical visit charge and a merchant-processing charge are different concepts and should remain separate in the model.

What changes when existing patients need to move?

Telegra has substantive public migration evidence. Its CSV migration documentation describes importing patients, products, coupons, orders and subscriptions, with dry-run validation and controlled production import. That should be acknowledged rather than claiming migration is unique to TEHR.

However, an import API does not establish outbound export terms or guarantee that all clinical records and payment credentials can move to another platform. For a TEHR transition, identify the source of each data type and obtain authorized samples. Clinical notes, consents, lab results and active treatment require their own continuity plan alongside commerce records.

Use the Telegra-to-TEHR migration guide and migration checklist to define reconciliation. Test identifiers, order status, upcoming renewals and the next clinical action. A migration should protect the patient’s care path and avoid duplicate billing, rather than being judged only by how many rows were imported.

How should you interpret launch timelines?

Telegra’s Plus and Pro tables list 21-day onboarding. This is a published vendor timeline, but it should not be treated as a guaranteed patient-migration SLA or proof that every specialty and integration can launch on the same schedule.

Ask what the onboarding milestone includes. Is the pharmacy connected? Are the clinical protocols configured? Has the branded patient experience been tested? Are payment arrangements active? A useful TEHR comparison applies the same acceptance checklist to both proposals and identifies the customer’s required inputs.

If a launch includes an existing patient population, add a separate cutover plan. The first new patient and the next refill for a continuing patient are different acceptance cases. Test both before announcing a transition date to the whole customer base.

When should you choose TEHR or Telegra?

Choose TEHR for further evaluation if you want its operator-led launch or migration approach, the proposed administrative support and stated flat-fee economics. Its experience behind DudeMeds, Peptiders, TellyMeds and FansMeds should prompt practical questions about your workflow, not unsupported claims that rivals lack operating experience.

Choose Telegra for further evaluation if its integrated commerce, branded patient surfaces and documented import tooling fit your business. Confirm plan-specific features and recurring charges, particularly if a mobile app or your own pharmacy is central to the plan.

The Telegra alternatives guide compares other ways to assemble the operation. If you mainly want a clinical API, an integrated platform may be more than you need. If you want the commercial and administrative system as well, make sure a narrower backend proposal does not leave that work unassigned.

What should you request before making the decision?

Ask for an itemized proposal, a responsibility map and a demonstration using your actual program requirements. Record unresolved questions with an owner and a due date. Review the resource library for related definitions and operating checklists, then bring the current workflow and intended changes to a scoped discussion. A useful agreement identifies what the vendor will deliver, what your team must supply, how exceptions are handled and what evidence will demonstrate readiness. It should also explain the practical exit process, so future changes do not depend on assumptions about records, subscriptions or access.

For a wider category view, compare the white-label telehealth platform shortlist and the turnkey telehealth platform shortlist. Use the first to examine brand and architecture choices, and the second to assess which implementation and operating tasks a proposed package actually supplies.

What else should you know?